Mark Bush

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Julio Rosenstock, Jane E.B. Reusch, Mark Bush et al. · Diabetes Care · 2009 · 236 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

Jessica Matthews, Murray Stewart, Erika H. De Boever et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 197 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

Mark Bush, Jessica Matthews, Erika H. De Boever et al. · Diabetes Obesity and Metabolism · 2009 · 178 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans

Eugenii A. Rabiner, John D. Beaver, Aidan Makwana et al. · Molecular Psychiatry · 2011 · 105 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects

Hisham Ziauddeen, Samuel R. Chamberlain, Pradeep J. Nathan et al. · Molecular Psychiatry · 2012 · 104 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17